All Comments by Marwan Sabbagh
- API Colombian Trial of Crenezumab Missed Primary Endpoints
- Drilling Down into the CMS Aduhelm Decision—A Primer
- Aduhelm Administration Remains a Trickle, ARIA a Concern
- Donanemab Confirms: Clearing Plaques Slows Decline—By a Bit
- Do Platelets Provide a Platform for Aβ Aggregation?
- Bapineuzumab Phase 3: Target Engagement, But No Benefit
- Predictors of Survival in Patients With Parkinson Disease.